MORBO DI CROHN. IL-23p19 VS USTEKINUMAB. UN’OTTIMA META-ANALISI DEI 5 TRIAL TESTA A TESTA. DA “AMERICAN JOURNAL OF GASTROENTEROLOGY” (FREE!)
IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn’s Disease: A Meta-Analysis of Randomized Controlled Trials Claudia Dziegielewsk et al. Abstract…

